LEAVITT PARTNERS, LLC

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $20,000.00 income · posted Oct 20, 2025

Bills named in this filing 2

Lobbying activity 1

Health Issues

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.